In theory, companies could just manufacture drugs for foreign markets at plants that are not FDA-approved, thus rendering these drugs ineligible for reimportation to the U.S. market.
The future belongs to those companies that can succeed at investing and manufacturing abroad in countries like China, Thailand, Mexico, and the U.S. And not only manufacture abroad for foreign markets, but also for export to the Japanese home market.